Alx Oncology Holdings
Price & Volume
Stats
See moreOpen | $1.48 |
Previous Close | $1.44 |
Day Range | $1.45-$1.54 |
52W Range | $0.40-$2.27 |
Market Cap | $73.1M |
Shares Short | 1M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | -100% |
Gross Profit (12 Mos) | $107,000 |
Diluted EPS | -$2.01 |
News
See moreYahoo Finance • last month
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
Yahoo Finance • 2 months ago
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
Yahoo Finance • 2 months ago
ALX Oncology to Present at Upcoming Investor Conferences
Yahoo Finance • 2 months ago
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
About
CEO | Mr. Jason W. Lettmann |
Address | 323 Allerton Avenue, South San Francisco, CA, United States, 94080 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 44 |
